Earnings summaries and quarterly performance for TREACE MEDICAL CONCEPTS.
Executive leadership at TREACE MEDICAL CONCEPTS.
John T. Treace
Detailed
Chief Executive Officer
CEO
AJ
Aaron J. Berutti
Detailed
Senior Vice President, Sales
GM
Gaetano M. Guglielmino
Detailed
Chief Commercial Officer
ML
Mark L. Hair
Detailed
Chief Financial Officer
SM
Scot M. Elder
Detailed
Chief Legal & Compliance Officer, Corporate Secretary
SF
Sean F. Scanlan
Detailed
Chief Innovation Officer
Board of directors at TREACE MEDICAL CONCEPTS.
Research analysts who have asked questions during TREACE MEDICAL CONCEPTS earnings calls.
DA
Danielle Antalffy
UBS Group AG
3 questions for TMCI
Also covers: ABT, ATRC, BAX +15 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
3 questions for TMCI
Also covers: ATRC, BVS, CBLL +4 more
RN
Richard Newitter
Truist Securities
3 questions for TMCI
Also covers: AXNX, DXCM, GKOS +18 more
Ryan Zimmerman
BTIG
2 questions for TMCI
Also covers: ALC, GEHC, GKOS +23 more
Aaron Wukmir
Lake Street Capital Markets
1 question for TMCI
Also covers: ELMD, LFVN, ORGO +2 more
BH
Benjamin Haynor
Lake Street Capital Markets
1 question for TMCI
Also covers: BFLY, EKSO, IDXG +6 more
Felipe Lamar
Truist Securities
1 question for TMCI
Also covers: BBNX, SIBN, TNDM +1 more
Jayna Renee Francis
UBS
1 question for TMCI
Kallum Titchmarsh
Morgan Stanley
1 question for TMCI
Also covers: ATEC, AXNX, EMBC +5 more
RW
Rick Wise
Stifel Financial Corp
1 question for TMCI
Also covers: BDX, BSX, GEHC +8 more
RM
Robert Marcus
JPMorgan Chase & Co.
1 question for TMCI
Also covers: ABT, BAX, BDX +21 more
Recent press releases and 8-K filings for TMCI.
Treace Medical Reports Q4 2025 Revenue and Outlines 2026 Strategic Focus
TMCI
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- Treace Medical reported Q4 2025 revenues of $62.1-$62.5 million and experienced mid-single-digit bunion procedure volume growth in Q3 and Q4 2025, driven by new technology adoption.
- The company transformed its business in Q3 2025 by commercializing new 3D bunion technologies, including Nanoplasty, Percuplasty 3D MIS systems, and Speed MTP system, expanding its portfolio beyond Lapiplasty.
- For 2025, Treace Medical expected Q4 profitability and strong year-over-year improvements in Adjusted EBITDA, alongside a significant reduction in cash usage.
- The strategic focus for 2026 is to drive continued case volume growth by leveraging the expanded portfolio to penetrate existing customers' bunion cases and commercialize the next-generation Lapiplasty Lightning platform.
- Gross margins are projected to remain high (high 70s, close to 80%) across all product lines, even with new products having lower average selling prices (ASPs).
Jan 14, 2026, 3:30 PM
Treace Medical Concepts Discusses Q4 2025 Revenue, New Product Launches, and Financial Improvements
TMCI
Product Launch
Guidance Update
Revenue Acceleration/Inflection
Jan 14, 2026, 3:30 PM
Treace Medical Concepts, Inc. Provides 2025 Preliminary Results and 2026 Product Pipeline Update
TMCI
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Treace Medical Concepts, Inc. reported preliminary full-year 2025 revenue of $212.3 million to $212.7 million, indicating 2% year-over-year growth at the midpoint.
- The company anticipates achieving positive Adjusted EBITDA in Q4 2025, following negative Adjusted EBITDA in the first three quarters of 2025.
- Treace is expanding its product portfolio with new 2025 launches, including Percuplasty™, Nanoplasty®, IntelliGuide® PSI, and several Speed™ branded implants, with further technologies like Lapiplasty® Lightning™ and SpeedTMT™ planned for 2026.
- Approximately one-third of US Foot & Ankle Surgeons used Treace bunion systems in 2025, contributing to a total market penetration of 7.8% in 2025.
| Metric | FY 2025 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025E |
|---|---|---|---|---|---|
| Revenue ($USD Millions) | $212.3 - $212.7 | N/A | N/A | N/A | N/A |
| Adjusted EBITDA ($USD Millions) | N/A | -$3.8 | -$3.6 | -$2.6 | $2 |
Jan 14, 2026, 3:30 PM
Treace Medical Concepts Discusses 2025 Performance and 2026 Growth Strategy
TMCI
Product Launch
Revenue Acceleration/Inflection
Guidance Update
- Treace Medical transformed into a comprehensive bunion solutions company in Q3 2025, commercializing new 3D bunion technologies including Nanoplasty, Percuplasty, and Speed MTP, expanding its portfolio beyond Lapiplasty.
- The company reported Q4 2025 revenues of $62.1-$62.5 million, ahead of expectations , achieved a 55% year-over-year improvement in Adjusted EBITDA in 2024, and anticipates Q4 2025 profitability and a significant reduction in cash usage for the full year 2025.
- Treace Medical expects continued mid-single-digit case volume growth into 2026 and plans to commercialize its next-generation Lapiplasty Lightning platform by the end of 2026, while maintaining high gross margins (high 70s to 80%) across all product lines.
Jan 14, 2026, 3:30 PM
Treace Medical Concepts Announces Preliminary Q4 and Full-Year 2025 Revenue
TMCI
Earnings
Guidance Update
Demand Weakening
- Treace Medical Concepts reported preliminary, unaudited fourth quarter 2025 revenue between $62.1 million and $62.5 million, an approximate 9% decrease at the midpoint compared to the same period in 2024.
- For the full-year 2025, preliminary revenue was between $212.3 million and $212.7 million, an approximate 2% increase at the midpoint over the prior year, and was in-line with the previously provided guidance range.
- The company ended 2025 with approximately 3,337 active surgeons, a 6% increase compared to the prior year, with approximately 202 new active surgeon additions for full-year 2025.
- Treace anticipates delivering positive Adjusted EBITDA in Q4 2025.
- While not issuing full-year 2026 guidance at this time, the company expects continued positive procedure volume growth but also anticipates headwinds related to broader economic conditions, softer consumer sentiment, and product mix shifts.
Jan 13, 2026, 1:54 PM
Treace Medical Concepts Announces Preliminary Q4 and Full-Year 2025 Revenue
TMCI
Earnings
Guidance Update
Demand Weakening
- Treace Medical Concepts announced preliminary, unaudited fourth quarter 2025 revenue of $62.1 million to $62.5 million, representing an approximate 9% decrease at the midpoint compared to the same period in 2024.
- Preliminary full-year 2025 revenue is estimated between $212.3 million and $212.7 million, an approximate 2% increase at the midpoint over the prior year, which is in-line with the previously provided guidance.
- The company added approximately 202 new active surgeons in full-year 2025, ending the year with about 3,337 active surgeons, a 6% increase compared to the prior year.
- Treace is not issuing full-year 2026 guidance at this time but anticipates continued positive procedure volume growth despite headwinds related to broader economic conditions and softer consumer sentiment.
Jan 13, 2026, 12:05 PM
Treace Medical Secures $175 Million Debt Financing
TMCI
Debt Issuance
New Projects/Investments
- Treace Medical Concepts, Inc. (TMCI) has entered into a new five-year $175 million senior secured loan arrangement with credit funds managed by SLR Capital Partners.
- The arrangement consists of $60 million in term loans funded at close, $65 million of additional term loan availability, and a $50 million revolving credit facility.
- Proceeds from the new term loan were used to prepay the Company’s $50 million term loan and $4 million drawn under its previously-existing revolving credit facility.
- This financing aims to reinforce the balance sheet, enhance financial flexibility, and advance commercial strategies.
- Following the refinancing, Treace now has total liquidity of approximately $165 million.
Dec 18, 2025, 1:30 PM
Truth Medical Discusses Q4 Guidance Reduction, New Product Strategy, and Cash Burn Reduction at UBS Conference
TMCI
Guidance Update
Product Launch
Demand Weakening
- Truth Medical (TMCI) reported continued softness in demand for lapoplasty and an underlying softness in patient demand in Q3 and early Q4 2025, leading to a reduction in Q4 guidance.
- The company is expanding its product portfolio with two minimally invasive osteotomy solutions and a SpeedMTP bunion, great toe fusion system, aiming to address the 75% of bunions not currently reached by their existing lapoplasty system.
- Despite mid-single-digit bunion procedure volume growth in Q3 2025, the lower average selling price (ASP) of these new products is creating a dampening effect on revenue growth. This mix shift is expected to cause penetration growth to outpace revenue growth for a short period.
- TMCI is focused on reducing cash burn, achieving a 45% reduction this year compared to last year, and expects to maintain high 70% gross margins with its new product offerings.
Nov 10, 2025, 4:45 PM
Treace Medical Discusses Product Expansion, Q4 Guidance Reduction, and Market Dynamics
TMCI
Product Launch
Guidance Update
Demand Weakening
- Treace Medical is in a transformative phase, expanding its product portfolio beyond the Lapiplasty Bunion Correction System to address a broader range of bunion indications, including minimally invasive osteotomy solutions and a big toe fusion system, aiming to capture the 75% of bunions not currently addressed by Lapiplasty.
- The company reduced its Q4 guidance due to continued softness in Lapiplasty demand and an underlying softness in patient demand, compounded by a mix shift towards newer products with lower average selling prices.
- Despite revenue challenges, Treace Medical reported mid-single-digit bunion procedure volume growth in Q3 and is focused on driving top-line growth with its expanded portfolio, while also achieving a 45% reduction in cash burn this year compared to last.
- Gross margins are expected to remain in the high 70% range, as new products are designed to maintain healthy margins.
- Treace Medical is incorporating AI into its IntelliGuide technology for patient-specific instrumentation and pre-operative planning, and developing an app-based X-ray tool for surgeons.
Nov 10, 2025, 4:45 PM
Treace Medical discusses product expansion and Q4 guidance reduction
TMCI
Product Launch
Guidance Update
Demand Weakening
- Treace Medical (TMCI) is expanding its product portfolio beyond the Lapiplasty Bunion Correction System with new solutions targeting 75% of bunions not currently addressed, including minimally invasive osteotomy and great toe fusion systems.
- The company reported softness in Lapiplasty demand and patient deferrals, resulting in a reduction of Q4 guidance.
- Despite mid-single-digit bunion procedure volume growth in Q3, newer products have a lower average selling price, causing a mix shift that dampens revenue growth.
- Management anticipates maintaining gross margins in the high 70% range and has achieved a 45% reduction in cash burn this year compared to last year.
Nov 10, 2025, 4:45 PM
Quarterly earnings call transcripts for TREACE MEDICAL CONCEPTS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more